Survival of patients with metastatic renal cell carcinoma with or without brain metastases
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf387 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Noam Savion-Gaiger und 10 weiteren Autor:innen. Beteiligte Einrichtung: Yale Cancer Center, New Haven, CT 06520, United States. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Brain Neoplasms, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Historically, brain metastasis (BM) is associated with poor survival for patients with metastatic renal cell carcinoma (mRCC). The prognostic significance of BM in the immune checkpoint (ICI) era is unclear.
Methods
We performed a retrospective cohort study of patients diagnosed with clear cell RCC (ccRCC) between 2012-2023. We examined the association between BM and overall survival (OS) among patients by treatment type (with or without ICI in any line of therapy) and whether they had brain MRI screening.
Results
We identified 338 patients with metastatic ccRCC between 2012 and 2023, of whom 96 (28.4%) had BM. mOS from the time of metastatic ccRCC diagnosis was 54.3 months (mo) in patients without BM versus 37.3 mo in patients with BM (P = .03). Among patients who received ICI therapy, mOS was 66.4 mo in those without BM versus 37.7 mo in those with BM (P = .01). In patients who did not receive ICI therapy, mOS was 32.1 mo in those without BM versus 17.6 mo in those with BM (P = .4). In those with BM, mOS from the time of initial metastatic disease diagnosis was 86.7 mo for those who underwent MRI brain screening versus 27.9 mo for those who did not (P = .00016).
Conclusion
In our ccRCC population, OS for patients with metastatic ccRCC and brain metastases has improved in the era of ICI therapy. Brain metastases are associated with poor prognosis. Patients with brain metastases discovered on screening had improved overall survival compared to those with brain metastases discovered because of symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yale Cancer Center, New Haven, CT 06520, United States.
- Department of Neurosurgery, Yale School of Medicine, New Haven, CT 06510, United States.
- Department of Urology, Yale School of Medicine, New Haven, CT 06520, United States.
ORCID-Profile: Noam Savion-Gaiger, Mario Sznol, Michael E Hurwitz
Zitieren
APA
Savion-Gaiger, N., Considine, B., Hasson, N., Nelson, M., Chiang, V., Kluger, H. M., Braun, D. A., Schoenfeld, D., Sznol, M., Leapman, M. S., & Hurwitz, M. E. (2025). Survival of patients with metastatic renal cell carcinoma with or without brain metastases. The Oncologist. https://doi.org/10.1093/oncolo/oyaf387
Vancouver
Savion-Gaiger N, Considine B, Hasson N, Nelson M, Chiang V, Kluger HM, et al. Survival of patients with metastatic renal cell carcinoma with or without brain metastases. The Oncologist. 2025. doi:10.1093/oncolo/oyaf387
BibTeX
@article{SavionGaiger2025,
author = {Savion-Gaiger, Noam and Considine, Bryden and Hasson, Nitzan and Nelson, Melanie and Chiang, Veronica and Kluger, Harriet M and Braun, David A and Schoenfeld, David and Sznol, Mario and Leapman, Michael S and Hurwitz, Michael E},
title = {Survival of patients with metastatic renal cell carcinoma with or without brain metastases},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf387}
}
EUVIMED